Albumin (Human) 25%, United States Pharmacopeia (USP)

DRUG3 trials

Sponsors

Grifols Therapeutics LLC

Conditions

Macular DegenerationMultiple Sclerosis, Relapsing-RemittingPolyradiculoneuropathy, Chronic Inflammatory Demyelinating

Phase 2

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis

CompletedNCT00220779

Grifols Therapeutics LLCMultiple Sclerosis, Relapsing-Remitting

Start: 2002-12-31End: 2005-02-28Updated: 2016-04-27

Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration

CompletedNCT00220805

Grifols Therapeutics LLCMacular Degeneration

Start: 2004-01-31End: 2005-05-31Updated: 2016-03-21

Phase 3

Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

CompletedNCT00220740

Grifols Therapeutics LLCPolyradiculoneuropathy, Chronic Inflammatory Demyelinating

Start: 2004-04-30End: 2006-06-30Updated: 2016-03-23

Related Papers

Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy.

2010-09-0123 citations

Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance.

2010-07-2063 citations

Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.

2010-05-1083 citations

Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.

2008-02-01449 citations